로딩 중…
지수 로딩 중…
Samik Pharm.
014950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩8,410+29.98%
2026-06-19
Price Chart
Samik Pharm.
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 84.16B KRW |
| Revenue | 60.02B KRW |
| Net Income | -2.19B KRW |
| Total Assets | 85.22B KRW |
| Net Assets | 68.98B KRW |
| Value | |
| P/B | 1.22x |
| P/S | 1.40x |
| EV/EBITDA | 76.69x |
| FCF Yield | -2.98% |
| Profitability | |
| ROE | -3.17% |
| ROA | -2.57% |
| Op. Margin | 1.77% |
| Financial Health | |
| Debt Ratio | 23.54% |
| Total Debt | 2.68B KRW |
| FCF | -2.51B KRW |
| Cash | 5.22B KRW |
| Current Ratio | 4.85x |
| Net Debt/EBITDA | -2.38x |
| Dividend | |
| Div. Yield | 0.62% |
| Performance | |
| 1M Return | 15.36% |
| From 52W High | -66.43% |
| 1Y MDD | -73.38% |
| Trading | |
| Volume | 6,612,991 shares |
| Foreign Own. | 2.39% |
| Per Share | |
| EPS | -77 KRW |
| BPS | 7,597 KRW |
Company Info
Established in 1980 for pharmaceutical manufacturing and sales, the company founded its subsidiary, PharmBay, for specialized pharmaceutical distribution in 2020, which was listed on KOSDAQ in 2025. It specializes in cardiovascular treatments for hypertension and hyperlipidemia, as well as diabetes treatments, handling 126 professional pharmaceutical products. Cardiovascular drugs, diabetes drugs, and CMO business account for 47%, 10%, and 12% of sales, respectively, with the company enhancing competitiveness by expanding its chronic disease treatment lineup. Samik Pharm was founded in 1980 and is headquartered in Bupyeong-gu, Incheon.